Skip to content
Screener

Axsome Therapeutics AXSM Q3 2025 earnings

Reported November 3, 2025 · Before market open

Revenue$171.0MMiss by $20.3M
EPS-$0.94Miss by $0.12
Revenue estimate$191.3M
EPS estimate-$0.82

Next report

Nov 2, 2026 (in a month)
Revenue estimate$258.3M
EPS estimate-$0.49

Financials

Q3 2025

Income statement

See full
Revenue$171.0M+63.2%
Gross profit$159.1M+65.1%
Operating income-$46.1M+26.4%
Net income-$47.2M+26.9%
EPS (diluted)-$0.94+29.9%

Balance sheet

See full
Cash & equivalents$325.3M-0.6%
Total debt$218.6M+13.7%
Total equity$73.7M-20.6%
Total assets$669.3M+19.2%

Cash flow

See full
Operating cash flow-+100%
CapEx$58.0K-35.6%
Free cash flow-+100%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$6.06B+41.8%
Enterprise value$5.95B+43.8%
P/S10.8×-1.8×

Profitability

See full
Gross margin91.9%+0.8pp
Operating margin-37.8%-13.9pp
Net margin-40.9%-14.6pp
FCF margin-18.2%-6.4pp

Returns & leverage

See full
Return on equity-275.5%+423pp
Debt / equity3×+0.9×
Current ratio1.6×-0.9×

FAQ

When did Axsome Therapeutics report Q3 2025 earnings?
Axsome Therapeutics (AXSM) reported Q3 2025 earnings on November 3, 2025 before market open.
What were Axsome Therapeutics's Q3 2025 revenue and EPS?
Axsome Therapeutics reported revenue of $171.0M and eps of $-0.94 for Q3 2025.
Did Axsome Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $191.3M by $20.3M. EPS missed the consensus estimate of $-0.82 by $0.12.
How did Axsome Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 63.2% from $104.8M a year earlier and eps grew 29.9% from $-1.34.
Where can I find Axsome Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-261651) and the 10-Q periodic report (0001193125-25-262664) directly on SEC EDGAR. The filing index links above go to sec.gov.